Narrow search
Showing 1 - 10 of 135
Cover Image
Impact and cost-effectiveness of a universal strategy to promote physical activity in primary care: population-based Cohort study and Markov model
Gulliford, Martin; Charlton, Judith; Bhattarai, Nawaraj; … - In: The European Journal of Health Economics 15 (2014) 4, pp. 341-351
A universal strategy to promote physical activity in primary care has the potential to increase life years lived free from physical disease. There is only weak evidence that a universal intervention strategy might prove cost-effective. </AbstractSection> Copyright The Author(s) 2014
Persistent link: https://www.econbiz.de/10010993819
Cover Image
Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data
Frey, Simon; Linder, Roland; Juckel, Georg; Stargardt, Tom - In: The European Journal of Health Economics 15 (2014) 2, pp. 133-142
We use longitudinal patient-level data from a German sickness fund with 7.26 million insured in a Markov-simulation model to assess the cost-effectiveness of long-acting injectable risperidone (LAI-RIS) compared with long-acting injectable flupentixol (LAI-FLX) in the long-term management of...
Persistent link: https://www.econbiz.de/10010993904
Cover Image
Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach
Jürgensen, Jan; Arns, Wolfgang; Haß, Bastian - In: The European Journal of Health Economics 11 (2010) 1, pp. 15-25
Persistent link: https://www.econbiz.de/10009404265
Cover Image
Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study
Taylor, Douglas; Pandya, Ankur; Thompson, David; Chu, Paula - In: The European Journal of Health Economics 10 (2009) 3, pp. 255-265
Persistent link: https://www.econbiz.de/10005004366
Cover Image
Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany
Brüggenjürgen, B.; Lindgren, P.; Ehlken, B.; … - In: The European Journal of Health Economics 8 (2007) 1, pp. 51-57
Persistent link: https://www.econbiz.de/10005167122
Cover Image
Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain
Antonanzas, Fernando; Rive, Benoit; Badenas, Josep; … - In: The European Journal of Health Economics 7 (2006) 2, pp. 137-144
Persistent link: https://www.econbiz.de/10005391162
Cover Image
Decision-analytical modelling in health-care economic evaluations
Sun, Xin; Faunce, Thomas - In: The European Journal of Health Economics 9 (2008) 4, pp. 313-323
Persistent link: https://www.econbiz.de/10005167131
Cover Image
The influence of waiting times on cost-effectiveness: a case study of colorectal cancer mass screening
Chauvin, Pauline; Josselin, Jean-Michel; Heresbach, Denis - In: The European Journal of Health Economics 15 (2014) 8, pp. 801-812
colorectal cancer. Using Markov modeling, we compare the standard Guaiac fecal occult blood test (gFOBT) with an innovative … screening test for colorectal cancer, namely the immunological fecal occult blood test (iFOBT). Waiting time can occur between a …
Persistent link: https://www.econbiz.de/10011151225
Cover Image
Modeling stroke management: a qualitative review of cost-effectiveness analyses
Guilhaume, Chantal; Saragoussi, Delphine; Cochran, John; … - In: The European Journal of Health Economics 11 (2010) 4, pp. 419-426
Persistent link: https://www.econbiz.de/10008456150
Cover Image
Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in cancer patients
Sabariego, C.; Brach, M.; Herschbach, P.; Berg, P.; … - In: The European Journal of Health Economics 12 (2011) 5, pp. 489-497
Persistent link: https://www.econbiz.de/10009324983